These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 21947251

  • 1. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
    Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, Schwartzkopf C, Nguyen-Tran V, Hollenbeck T, McNamara P, He X, Liu H, Seidel HM, Jaton AL, Gromada J, Teixeira S.
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
    [Abstract] [Full Text] [Related]

  • 2. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
    Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, Choi SH, Yang EK, Park KJ, Chae HW, Moon HS, Kim SH, Shin YG, Yoon SH.
    Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
    [Abstract] [Full Text] [Related]

  • 3. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, Vickers SP, Clifton PG.
    Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
    [Abstract] [Full Text] [Related]

  • 4. Efficacy in diet-induced obese mice of the hepatotropic, peripheral cannabinoid 1 receptor inverse agonist TM38837.
    Cooper ME, Nørregaard PK, Högberg T, Andersson G, Receveur JM, Linget JM, Elling CE.
    Br J Pharmacol; 2024 Oct; 181(20):3926-3943. PubMed ID: 38886096
    [Abstract] [Full Text] [Related]

  • 5. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ, Serrano A, Pérez-Valero V, Jagerovic N, Hernández-Folgado L, Bermúdez-Silva FJ, Macías M, Goya P, de Fonseca FR.
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [Abstract] [Full Text] [Related]

  • 6. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
    Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH.
    Diabetes; 2008 Nov; 57(11):2977-91. PubMed ID: 18716045
    [Abstract] [Full Text] [Related]

  • 7. Pyrazole antagonists of the CB1 receptor with reduced brain penetration.
    Fulp A, Zhang Y, Bortoff K, Seltzman H, Snyder R, Wiethe R, Amato G, Maitra R.
    Bioorg Med Chem; 2016 Mar 01; 24(5):1063-70. PubMed ID: 26827137
    [Abstract] [Full Text] [Related]

  • 8. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
    Järbe TU, LeMay BJ, Olszewska T, Vemuri VK, Wood JT, Makriyannis A.
    Pharmacol Biochem Behav; 2008 Nov 01; 91(1):84-90. PubMed ID: 18640150
    [Abstract] [Full Text] [Related]

  • 9. Cannabinoid CB1 receptor inverse agonist MJ08 stimulates glucose production via hepatic sympathetic innervation in rats.
    Chen W, Liu H, Guan H, Xue N, Wang L.
    Eur J Pharmacol; 2017 Nov 05; 814():232-239. PubMed ID: 28844874
    [Abstract] [Full Text] [Related]

  • 10. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z, Wu NN, Zhao W, Chain DC, Schaffer E, Zhang X, Yamdagni P, Palejwala VA, Fan C, Favara SG, Dressler HM, Economides KD, Weinstock D, Cavallo JS, Naimi S, Galzin AM, Guillot E, Pruniaux MP, Tocci MJ, Polites HG.
    Obesity (Silver Spring); 2011 Oct 05; 19(10):1923-34. PubMed ID: 21799481
    [Abstract] [Full Text] [Related]

  • 11. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A.
    J Pharmacol Exp Ther; 2012 Feb 05; 340(2):433-44. PubMed ID: 22085649
    [Abstract] [Full Text] [Related]

  • 12. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
    Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.
    Am J Physiol Endocrinol Metab; 2014 Feb 15; 306(4):E457-68. PubMed ID: 24381003
    [Abstract] [Full Text] [Related]

  • 13. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice.
    Gamble-George JC, Conger JR, Hartley ND, Gupta P, Sumislawski JJ, Patel S.
    Psychopharmacology (Berl); 2013 Aug 15; 228(3):401-9. PubMed ID: 23483200
    [Abstract] [Full Text] [Related]

  • 14. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A, Gulyás B, Varnäs K, Little PB, Noerregaard PK, Jensen NO, Elling CE, Halldin C.
    Synapse; 2014 Mar 15; 68(3):89-97. PubMed ID: 24293119
    [Abstract] [Full Text] [Related]

  • 15. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Zhu B, Matthews JM, Xia M, Black S, Chen C, Hou C, Liang Y, Tang Y, Macielag MJ.
    Bioorg Med Chem Lett; 2016 Nov 15; 26(22):5597-5601. PubMed ID: 27671499
    [Abstract] [Full Text] [Related]

  • 16. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
    Erdozain AM, Diez-Alarcia R, Meana JJ, Callado LF.
    Biochem Pharmacol; 2012 Jan 15; 83(2):260-8. PubMed ID: 22093909
    [Abstract] [Full Text] [Related]

  • 17. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
    Tallett AJ, Blundell JE, Rodgers JR.
    Behav Pharmacol; 2007 Nov 15; 18(7):591-600. PubMed ID: 17912043
    [Abstract] [Full Text] [Related]

  • 18. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR.
    Can J Physiol Pharmacol; 2014 Dec 15; 92(12):975-83. PubMed ID: 25361428
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP, Stribling DS, Camacho RE, Rosko KM, Wang J, Tong S, Feng Y, Marsh DJ, Yu H, Guan X, Spann SK, Macneil DJ, Fong TM, Metzger JM, Goulet MT, Hagmann WK, Plummer CW, Finke PE, Mills SG, Shah SK, Truong Q, Van der Ploeg LH, Macintyre DE, Strack AM.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):215-24. PubMed ID: 18021763
    [Abstract] [Full Text] [Related]

  • 20. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A, Del Arco I, Javier Pavón F, Macías M, Perez-Valero V, Rodríguez de Fonseca F.
    Neuropharmacology; 2008 Jan 28; 54(1):226-34. PubMed ID: 17467748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.